Change of Adviser

RNS Number : 3615Z

Diaceutics PLC

21 May 2021

 

21 May 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Change of Nominated Adviser

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the appointment of Stifel Nicolaus Europe Limited as Nominated Advisor and Sole Corporate Broker with immediate effect.

Enquiries: 

Diaceutics PLC Peter Keeling, Chief Executive Officer Philip White, Chief Financial Officer	www.diaceutics.com via Alma PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison  Stewart Wallace Nick Adams	[phone]
Alma PR Caroline Forde Robyn Fisher Kieran Breheny	[phone] or [e-mail]

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries.  www.diaceutics.com

About DXRX - The Diagnostic Network®

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.  

 

END

 

 

APPURAWRAUUVUAR